File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Potential therapeutic role of interleukin 9 in a mouse lung cancer model

TitlePotential therapeutic role of interleukin 9 in a mouse lung cancer model
Authors
Issue Date2020
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
25th Medical Research Conference 2020, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 19, abstract no. 27 How to Cite?
AbstractIntroduction: Lung cancer is still the leading cause of cancer-related death. Mounting evidence indicated that interleukin 9 (IL-9) was linked to cancer. However, its role in lung cancer is still controversial. In this study, we aimed to explore the therapeutic role of IL-9 in lung cancer and to elucidate its mechanism. Methods: Mouse Lewis lung carcinoma (LLC) cells and human lung cancer cell lines (H1975, A549, HCC827) were purchased from ATCC. Western blot was used to detect the IL-9 receptor expression. MTT assay was conducted to explore the effect of IL-9 on human lung cancer cell lines. Lewis lung carcinoma mouse model was established by subcutaneous injection of 500000 LLC cells. At day 7, the mice were randomised and divided into control and IL-9 group. In IL-9 arm, mice were treated with IL-9 intraperitoneally (50 ng/mouse, 3 times/ week). The body weight of mice and tumour volume were measured every other day. Results: Interleukin 9 receptor was found in all human lung cancer cell lines, but not in LLC. Interleukin 9 inhibited cell proliferation in human lung cancer cell lines. After incubation of 50 ng/mL IL-9 for 48 hours, about 20% to 40% reduction of cell growth was observed. Moreover, IL-9 suppressed the tumour growth in LLC mouse model. The relative tumour volume in the IL-9 treatment arm was 69% that of the control group at the end of treatment (P=0.0295). Conclusion: Interleukin 9 slightly inhibited growth of human lung cancer cell lines only possibly due to endogenous expression of IL-9 receptor in those cell lines. In contrast, IL-9 suppressed tumour growth in LLC mouse model. The underlying mechanisms remain to be elucidated. Acknowledgement This study was supported by YC Chan Scientist Award 2019 and Donation from Lifestyle International Holdings Limited.
Persistent Identifierhttp://hdl.handle.net/10722/286453
ISSN
2019 Impact Factor: 1.679
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorFeng, Y-
dc.contributor.authorYan, S-
dc.contributor.authorLam, SK-
dc.contributor.authorHo, JCM-
dc.date.accessioned2020-08-31T07:04:05Z-
dc.date.available2020-08-31T07:04:05Z-
dc.date.issued2020-
dc.identifier.citation25th Medical Research Conference 2020, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 19, abstract no. 27-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/286453-
dc.description.abstractIntroduction: Lung cancer is still the leading cause of cancer-related death. Mounting evidence indicated that interleukin 9 (IL-9) was linked to cancer. However, its role in lung cancer is still controversial. In this study, we aimed to explore the therapeutic role of IL-9 in lung cancer and to elucidate its mechanism. Methods: Mouse Lewis lung carcinoma (LLC) cells and human lung cancer cell lines (H1975, A549, HCC827) were purchased from ATCC. Western blot was used to detect the IL-9 receptor expression. MTT assay was conducted to explore the effect of IL-9 on human lung cancer cell lines. Lewis lung carcinoma mouse model was established by subcutaneous injection of 500000 LLC cells. At day 7, the mice were randomised and divided into control and IL-9 group. In IL-9 arm, mice were treated with IL-9 intraperitoneally (50 ng/mouse, 3 times/ week). The body weight of mice and tumour volume were measured every other day. Results: Interleukin 9 receptor was found in all human lung cancer cell lines, but not in LLC. Interleukin 9 inhibited cell proliferation in human lung cancer cell lines. After incubation of 50 ng/mL IL-9 for 48 hours, about 20% to 40% reduction of cell growth was observed. Moreover, IL-9 suppressed the tumour growth in LLC mouse model. The relative tumour volume in the IL-9 treatment arm was 69% that of the control group at the end of treatment (P=0.0295). Conclusion: Interleukin 9 slightly inhibited growth of human lung cancer cell lines only possibly due to endogenous expression of IL-9 receptor in those cell lines. In contrast, IL-9 suppressed tumour growth in LLC mouse model. The underlying mechanisms remain to be elucidated. Acknowledgement This study was supported by YC Chan Scientist Award 2019 and Donation from Lifestyle International Holdings Limited.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.relation.ispartofMedical Research Conference 2020-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titlePotential therapeutic role of interleukin 9 in a mouse lung cancer model-
dc.typeConference_Paper-
dc.identifier.emailYan, S: ssyan@hku.hk-
dc.identifier.emailLam, SK: sklam77@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.authorityHo, JCM=rp00258-
dc.identifier.hkuros313093-
dc.identifier.volume26-
dc.identifier.issue1, Suppl. 1-
dc.identifier.spage19, abstract no. 27-
dc.identifier.epage19, abstract no. 27-
dc.publisher.placeHong Kong-
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats